University of Rhode Island

DigitalCommons@URI
Open Access Dissertations
2017

Novel Methods for Delivering and Promoting the Endosomal
Escape of Nucleic Acid Based Drugs: Chiral Polyamines and
Hydrophobic Nanoparticle-Containing Liposomes
Ruchi Verma
University of Rhode Island, ruchi_verma@uri.edu

Follow this and additional works at: https://digitalcommons.uri.edu/oa_diss

Recommended Citation
Verma, Ruchi, "Novel Methods for Delivering and Promoting the Endosomal Escape of Nucleic Acid Based
Drugs: Chiral Polyamines and Hydrophobic Nanoparticle-Containing Liposomes" (2017). Open Access
Dissertations. Paper 616.
https://digitalcommons.uri.edu/oa_diss/616

This Dissertation is brought to you for free and open access by DigitalCommons@URI. It has been accepted for
inclusion in Open Access Dissertations by an authorized administrator of DigitalCommons@URI. For more
information, please contact digitalcommons@etal.uri.edu.

NOVEL METHODS FOR DELIVERING AND PROMOTING THE ENDOSOMAL
ESCAPE OF NUCLEIC ACID BASED DRUGS: CHIRAL POLYAMINES AND
HYDROPHOBIC NANOPARTICLE-CONTAINING LIPOSOMES
BY
RUCHI VERMA

A DISSERTATION SUBMITTED IN PARTIAL FULFILLMENT OF THE
REQUIREMENTS FOR THE DEGREE OF
DOCTOR OF PHILOSOPHY
IN
PHARMACEUTICAL SCIENCES

UNIVERSITY OF RHODE ISLAND
2017

DOCTOR OF PHILOSOPHY DISSERTATION
OF
RUCHI VERMA

APPROVED:
Dissertation Committee:
Major Professor

Roberta S. King
David R. Worthen
Joel M. Chandlee
Nasser H. Zawia
DEAN OF THE GRADUATE SCHOOL

UNIVERSITY OF RHODE ISLAND
2017

ABSTRACT

Nucleic acid based drugs such as plasmid DNA (pDNA), small interfering RNA
(siRNA), short hairpin RNA (shRNA), micro RNA (miRNA), and both antisense and
antigene oligonucleotides, are potentially potent and specific compounds for therapeutic
applications. Many major life threatening ailments might be treated using these
molecules, and many polynucleotide products are currently in advanced clinical
development. However, their successful therapeutic application is hindered due to limited
delivery to their site of action in either the cytosol or the nucleus of a cell. Some of the
barriers in the path of successful delivery of these biomolecules to their site of action
have been addressed. However, endosomal entrapment followed by maturation to
lysosomes and degradation of these compounds inside the cell is one remaining major
hurdle. This dissertation describes two novel siRNA delivery techniques which present
distinct advantages in their respective areas of application while, at the same time,
constitute promising platforms for developing therapeutic biologicals. Chapter 2 focuses
on liposomal delivery vehicles containing hydrophobic nanoparticles in their bilayers,
which encapsulate the nucleic acid based drugs and promote endosomal escape by
nanoparticle induced fusion with the endosomal membranes. Specifically we use metal
nanoparticles in specialized liposomes for the efficient delivery of small interfering RNA
(siRNA). Manuscript 2 focuses on novel chiral cationic polymers – polyethyleneimines
(PEIs) – that form complexes with the negatively charged nucleic-acid based drugs and
promote endosomal escape via a proton sponge effect. Specifically we use of chiral
cationic polyamines for two intriguing applications: fabrication of chiral covalently-

linked microcapsules, and enantiospecific delivery of siRNA to Huh 7 cells. We found
that two of the designed polymers improved transfection efficiency relative to
commercially available transfection reagents with lower cell toxicity. In total this
dissertation presents work that demonstrates novel and efficient delivery strategies that
promote endosomal escape and enhance the intracellular activity of nucleic acid based
drugs.

ACKNOWLEDGMENTS

I would like to Thank my major advisor Dr. Roberta King for playing an extremely
critical role during mentoring of me in my PhD program. It is very important for me to
acknowledge her leadership and strength of character in accepting me as her graduate
student. While growing up in India, I was always taught by my parents that a teacher is
the most influential element in every student’s life and we are mentored by them for
learning various aspects of life and its challenges. They are addressed as “Guru” in India.
Every Guru guides and walks his disciple with extreme sensitivity and patience, showing
them the path of patience and perseverance. I consider Dr. King as one such Guru in my
life, who not only taught me an important lesson of how to “Pick and choose your
battles” but also gave me the most beautiful gift of her humility. She has advised and
mentored me very efficiently and made me use my limited time and resources that were
available in a very efficient manner. She also guided me scientifically through out the
process of my comprehensive exams and shared best ideas during my proposal writing.
Dr. King, not only is fair and wise but is also realistic and focused in bringing out the best
in me under such extreme conditions, so that I perform to my best ability. All these
following deadlines were only possible with Dr. King’s undaunting support and
mentoring of me through out the process.
I also want to Thank Dr. David Rowley and Dr. David Worthen, who have been
standing rock solid to support students like me with extreme care and sensitivity. Dr.
Rowley is truly dynamic and quick with his honest support for students and does his best
as the Department chair of BPS. I am very Thankful to him for his strong support in my

iv

journey for completing this PhD. I cannot find enough words of acknowledgment and my
gratefulness for having Dr. David Worthen both in my PhD committee as well as one of
the major co-advisor on the project we did together. Dr. Worthen always has the best
interest for his students and is extremely approachable to them at every time of need. I
am truly blessed to receive his mentorship and guidance at every step of my program. He
has not only taught me scientific and critical reasoning, but also walked with me on the
path of all the challenging times, that I faced through out my journey in URI. He exhibits
a very strong character and works effortlessly around the clock for all his students. Dr.
Worthen’s strong scientific knowledge along with his patient and focused attitude has
tremendously brought out the best results through the project we have done together. He
is undoubtedly, the best mentor I could ask for and completes my circle of having a
“Guru” in my life. I really thank him for everything that he has helped me with. I wish
the best for him. The Ombudmun team, Prof Gerry Tyler and Prof. Alfred Killilea
provided me with a staunch support at every step and gave me the right emotional and
moral support to survive the sensitive, challenging situations at URI. They are extremely
precious and like “a feather in my cap” in pursuit of the hard-earned Doctorate degree.
I must not forget to Thank Dean Rusnock, whose absolute and wonderful
humbleness has provided me with significant emotional/work balance while she
considered me for another opportunity to still complete my PhD under the absolutely
stressful situations in URI. Her faith in helping students like me is clearly visible and I
offer my sincere Thank you for her support, as I prepare myself to walk with honor with a
very hard earned degree.

v

I would like to acknowledge the role played by my best friend, colleague,
undergraduate classmate and my confidante in life, Dr. Ashish L. Sarode. This is a man
who stood strongly by my side through out the entire time, ever since I entered URI, to
achieve my dream of completing my Ph.D. Just like any other best friends, we would
always talk about our big dreams to work together on our aims one day. We wanted to
contribute in areas of Cancer and Vitiligo, since these diseases have directly affected our
personal lives in the history of our family. My maternal grandfather fought in World War
–II and came back home with an incurable, late stage terminal stomach cancer. Ashish’s
mother has Vitiligo, which later got passed to his sister. Life came to a full circle when
we finally crafted our dream research project, in honor to contribute towards autoimmune
diseases, that now stands as a big hit with the major leading Biopharmaceutical
Industries. I am Thankful to have such a great partner like Ashish, with whom this
journey of research and good work has been so achievable.
I would also like to Thank Kim Andrews for her positive support and guidance
through out the entire time. My friends Hope, Sreeram Raju, Divya, Srinivas, Shalu,
Vishal jiju, Daniela, Rosemary Gatti, Alizandra, Elizabeth, Lexi, Steffani and Mayurika,
Thank you all. I am proud and thankful for my team at CCE, Providence, Tamara
Bolotow, Cessie and Dr. Edward Bozzi who gave me financial stability and positive
guidance all the time.
I wouldn’t have stood strong in my pursuit if I didn’t have the love and support of
my family, specially, my sisters Sushma and Payal. I love my dear nephews Laksh and
Agastya and my new niece Myra and hope that one day they will be able to read this
piece of work.

vi

I was emotional focused in my journey because I have the passionate, unconditional
love of my fur babies, Eva-Jones and Dollops. I am very grateful for their “paw-love”.

This thesis is dedicated to my loving parents, without whom this day in my life
would have not been possible. I love you both immensely. Thank you Ma and Papa.

vii

PREFACE

This dissertation has been written in a manuscript format. Chapter 1 includes brief
background material on the current state of the art regarding delivery methods for nucleic
acid based drugs. Chapter 2 is in manuscript format of the journal American Chemical
Society and is pending submission to the journal. Chapter 3 is in manuscript format of the
journal Bioorganic & Medicinal Chemistry Letters and has been published. Chapter 4
focuses on Future Work for manuscript 1. Chapter 5 includes brief summary and
conclusions tying the two manuscripts into a single whole. The appendices include work
conducted by the author but unrelated to the dissertation theme. The Bibliography lists all
the sources used or consulted in writing the entire dissertation in the style of American
Chemical Society format in alphabetical order by the last name of the first author.
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INTRODUCTION

Pharmaceutical research, in both academia and in industry, is increasingly focused
on the development of biotechnology-derived and genetically-engineered nucleic acid
based drugs such as plasmid DNA (pDNA), small interfering RNA (siRNA), short
hairpin RNA (shRNA), micro RNA (miRNA), and antisense- and antigeneoligonucleotides as potential therapeutics. These molecules can be highly target-specific
and potent, and they may be used to treat various life-threatening ailments{Alvarez-Salas,
2008 #67}. Allied Market ResearchTM has predicted that the global siRNA therapeutics
market alone is expected to reach $1.2 billion by the year 2020. While promising as
therapeutic agents, the delivery of these molecules is one of the most challenging aspects
of their development. Nucleic acid based drugs are very hydrophilic, are of high
molecular weight, are often chemically and enzymatically unstable, and are highly
charged molecules{Oliveira, 2006 #65}. These molecules face many hurdles before they
reach their target site of action, such as rapid renal clearance, serum degradation,
opsonization, reticuloendothelial system (RES) uptake and metabolism, insufficient tissue
and cell internalization, endosomal degradation, and immunosensitization.{Wang, 2010
#69} Hence, in order to use these drugs therapeutically, it is necessary to develop
vehicles and methods for their efficient delivery to their site of action.
Among various potential delivery approaches, the use of self-assembling lipids in
order to develop vesicular delivery vehicles has proven to be one of the successful and
feasible approaches.5 In particular, small unilamellar vesicles (SUVs) such as liposomes
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are popular carriers for nucleic acid based drugs because of their favorable characteristics
such as biocompatibility, biodegradability, spontaneous self-assembly, the ease of largescale production, and suitability for clinical application.{Musacchio, 2011 #71} Some of
the barriers in the path of efficient delivery of nucleic acid based drugs to their site of
action have been addressed using liposomal delivery systems{Schroeder, 2010 #70}. For
instance, the stability and plasma half life of liposomes may be enhanced by adding
neutral or charged lipids, cholesterol, and polyethylene glycol (PEG) to the formulation.
The lipids stabilize the liposomal bilayer by reducing repulsion between similar charges,
and by inducing steric hindrance to the liposome surfaces. Similarly, cholesterol embeds
in the hydrophobic domains of the bilayer and enhances structural rigidity and facilitates
cellular uptake by improving endosomal internalization. PEG chains extend out of the
lipid bilayer and provide a shield of steric hindrance on the positive charge that prevents
interaction with opsonins and subsequent RES uptake. However, PEG chains also
interfere with cellular uptake and endosomal escape. Hence, transient PEG coating
strategies have been utilized, wherein exchangeable or reducible PEG linkages such as
PEG-ceramide, disulfide-PEG, and orthoester-PEG lipids are used{Romberg, 2008 #72}.
Moreover, the attachment of targeting ligands at the distal end of PEG moieties has
assisted in cell specific uptake. However, despite many efforts and advances in these
delivery vehicles, endosomal degradation of their cargo remains one of the pivotal
challenges{Varkouhi, 2011 #73}. Hence, there is a pressing need to develop novel
techniques to promote the endosomal escape of biologics before they are degraded in
endosomes. In this investigation we evaluated novel methods to promote the endosomal
escape of liposome-encapsulated polynucleotides to address this issue.
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Another option for cellular deliveries, specifically of negatively charged
polynucleotides and nucleic acids based drugs are cationic polymers{Tamura, 2010 #81}.
Among these cationic polymers, polyethylenimines (PEIs) are most popular due to their
relatively higher transfection efficiency. Under physiological conditions, PEIs are
protonated and can form ionic complexes with nucleic acids, which are then taken up by
the cells via caveolae- or clathrin-mediated pathways, resulting in efficient
transfection{Gunther, 2011 #82}. The transfection efficiency of PEIs is also attributable
to their facilitated endosomal escape due to a proton sponge effect{Behr, 1997
#84;Boussif, 1995 #83;Sonawane, 2003 #85}. The proton sponge effect takes place due
to the acidification of endosomes after internalization that leads to protonation of the
amine groups of the PEIs, which causes an influx of additional protons and chloride ions.
Consequently, water molecules enter the endosome to equilibrate the resulting osmotic
imbalance, resulting in rupture of endosomal membranes due to inflation{Tseng, 2009
#86}. Although there are many reported examples of PEIs used for siRNA and DNA
delivery, many of these delivery vehicles suffer from high cytotoxicity. The
physicochemical properties of the PEIs play an important role in determining their
relative efficiency and toxicity. For example, increased molecular weight of polyethylene
imines (PEIs) increases their cytotoxicity, whereas very low molecular weight PEIs
depict poor transfection efficiency{Fischer, 1999 #88;Godbey, 1999 #87}. Thus, the
development of PEI delivery agents, which exhibit both delivery efficacy and minimal
toxicity, remains a challenge. In this investigation we evaluated novel chiral PEIs as
efficient and relatively less toxic delivery vehicles.
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CHAPTER 1

MANUSCRIPT 1
Preparing to submit it to American Chemical Society

Discovery of an Innovative Pathway for Endosomal Escape of Nucleic Acid-Based
Drugs: Nanoparticle Induced Fusogenicity in Liposomal Bilayers.

Ruchi Verma, Ashish Sarode and David R. Worthen
University of Rhode Island, Kingston, RI, USA
Corresponding author: Ruchi Verma

Biomedical and Pharmaceutical Sciences
Colleges of Pharmacy
University of Rhode Island
Kingston, RI 02881
508-409-8731
Ruchi_verma@.uri.edu
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ABSTRACT
In this work we describe novel compositions and methods of use of formulations
designed for the efficient delivery of nucleic acid-based drugs to their site of action. We
discovered that the incorporation of hydrophobic metal nanoparticles into the membranes
of vesicular delivery vehicles, such as liposomes, enhance the endosomal membrane
fusogenicity and endosomal escape of these delivery vehicles. This observed
enhancement in fusogenicity is attributed to nanoparticle-mediated promotion of inverted
hexagonal phase formation in lipid bilayers. As a result, the vesicular delivery vehicles
more readily fuse with the endosomal bilayer, thereby leading to enhanced endosomal
escape of the vesicular delivery vehicle, thus facilitating the delivery of biologically
active molecules to their sites of action. We successfully demonstrated inverted
hexagonal phase formation due to the presence of hydrophobic nanoparticles of gold or
silver in the bilayers using 31P-NMR spectroscopy. The promotion of inverted hexagonal
phase formation was greater for higher concentrations and larger sized nanoparticles were
incorporated into the liposomes. The enhancement in transfection efficiency due to the
presence of nanoparticles was demonstrated for pDNA and siRNA for eGFP expression
using fluorescence microscopy and FACS analysis, whereas that for pDNA of mFXRa1
was shown using Western blot.

1. Introduction
Pharmaceutical research, in both academia and in industry, is increasingly focused
on the development of biotechnology-derived and genetically-engineered nucleic acid
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based drugs such as plasmid DNA (pDNA, small interfering RNA (siRNA), short hairpin
RNA (shRNA), micro RNA (miRNA), antisense, and antigene oligonucleotides as
potential therapeutics. These molecules are highly specific and potent and can be used to
treat various life-threatening ailments.1 Allied Market ResearchTM has predicted that the
global siRNA therapeutics market alone is expected to reach $1.2 billion by the year
2020. While promising as therapeutic agents, the delivery of these molecules is one of the
most important and challenging aspects of their development, and is the focus of
extensive industrial and academic research efforts.2 Nucleic acid-based drugs are very
hydrophilic, are of high molecular weight, are often chemically- and enzymatically
unstable, and are highly charged molecules.3 If administered naked, these molecules face
many hurdles before they reach their target site of action, such as rapid renal clearance,
serum degradation, opsonization, RES uptake and metabolism, insufficient tissue and cell
internalization, and endosomal degradation, as well as immunosensitization.4 Hence, in
order to use these drugs therapeutically, it is necessary to develop vehicles for their
efficient delivery to their site of action. Among various potential formulation methods,
the use of self-assembling lipids and polymers in order to develop vesicular delivery
vehicles such as lipsomes and polymersomes has proven to be one of the successful and
feasible approaches. Despite many efforts and advances in these delivery vehicles,
endosomal degradation of their cargo remains one of the pivotal challenges. Hence, there
is a pressing need to develop novel techniques to promote endosomal escape of biologics
before they are degraded in the endosome. The present investigation describes a novel
method designed to address this need.
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Liposomal delivery systems are popular carriers for nucleic acid-based drugs
because of their favorable characteristics such as biocompatibility, biodegradability,
spontaneous self-assembly, the ease of large-scale production, and suitability for clinical
application5. Some of the barriers in the path of efficient delivery of nucleic acid based
drugs to their site of action have been addressed using liposomal delivery systems6. For
instance, the stability and plasma half life of liposomes may be enhanced by adding
neutral lipids, cholesterol, and polyethylene glycol (PEG) to the lipid formulation. The
neutral lipids stabilize the liposomal bilayer by reducing repulsion between similar
charges. Similarly, cholesterol embeds in the hydrophobic domains of the bilayer and
enhances structural rigidity as well as facilitates cellular uptake by improving endosomal
internalization. PEG chains extend out of the lipid bilayer and provide a shield of steric
hindrance on the surface of the liposome which reduces interactions with opsonins and
subsequent RES uptake. However, PEG chains also interfere with cellular uptake and
endosomal escape. Hence, transient PEG coating strategies have been utilized, wherein
exchangeable or reducible PEG linkages such as PEG-ceramide, disulfide-PEG, and
orthoester-PEG lipids are used7. Moreover, the attachment of targeting ligands at the
distal end of PEG moieties has improved cell-specific uptake.

Endosomal degradation is still one of the major barriers to the efficient delivery of
nucleic acid-based drugs8. Various approaches, such as fusion in the endosomal
membrane, a proton sponge effect, pore formation in the endosomal membrane, and
photochemical disruption of the endosomal membrane have been assessed in order to
address this issue9. From among these strategies, the fusion of the liposomal and
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endosomal membranes and the subsequent release of the liposomal cargo into the cytosol
has been perhaps the most promising one10. This membrane fusion occurs via inverted
hexagonal (HII) phase formation between liposomal and endosomal bilayers. The HII
phase formation can be enhanced by increasing negative interfacial curvature of the
liposomal bilayer using lipids with appropriate critical packing parameters11. For
instance, by using lipids with higher unsaturation in their chains generates a kink that
assists in HII phase formation by increasing negative interfacial curvature12-14. A packing
frustration is generated in the hydrophobic domains of the lipids while the HII phase is
being formed due to creation of voids around the hydrophilic channels of the HII phase15.
In this investigation we hypothesized that the presence of free flowing hydrophobic
nanoparticles (NPs) in the liposomal bilayers would increase their negative interfacial
curvature as well as satisfy the packing frustration during HII phase formation by filling
up the voids in the hydrophobic domains. Hence, various hydrophobic metal NPs of
different sizes were incorporated into the liposomal bilayers at different concentrations,
and the enhancement in fusogenicity and subsequent increase in transfection efficiency of
these NPs-containing liposomal delivery vehicles was demonstrated in this work.

Materials
The eGFP expressing plasmid DNA (pDNA) was obtained from Origene, eGFP specific
silencing siRNA from Qiagen and mouse FXRa1 protein expressing plasmid construct
from Dr. Mathew Stonner (Biomedical and Pharmaceutical Sciences, University of
Rhode Island). The non-ionic lipid DSPC (1,2-distearoyl-sn-glycero-3-phosphocholine),
the cationic lipid DOTMA (1,2-di-O-octadecenyl-3-trimethylammonium propane
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chloride salt), and the anionic lipid (1,2-dipalmitoyl-sn-glycero-3-phospho-L-serine
sodium salt) were obtained from Avanti Polar Lipids, Inc. (Alabama, USA). Oleic acidcoated hydrophobic SPIO maghemite NPs (5 nm, 24 mg mL−1, or 187.9 mM Fe2O3)
dispersed in chloroform were purchased from Ocean Nanotech (Springdale, AR, USA).
Dodecanethiol-coated hydrophobic gold (2 nm) and silver (4 nm) NPs dispersed in
hexane were obtained from Nanocomposix (San Diego, CA, USA). The transfection
reagent GenJet-II and the cell culture medium, Gibco’s OPTIMEM-1 (Reduced FBS),
was obtained from ThermoFisher Scientific. Huh-7 cells were purchased from ATCC
and primary antibody for mouse FXR (H-130) (SC-13063) and mouse GAPDH from
Santacruz Inc. Negative control siRNA (20 nmol) was purchased from Qiagen.

2. Methods
2.1. Preparation of liposomes
Liposomes were prepared by thin film hydration method.16 Briefly, a chloroform
solution of cationic lipid DOTMA and non-ionic lipid DSPC at an equal molar ratio
with/without hydrophobic NPs at various ratios of lipid molecules : NPs was prepared in
a glass vial. A thin uniform film was then prepared by rapidly evaporating the organic
solvent under vacuum for 2 hours in order to remove the trace solvent. This film was then
hydrated using 0.5 ml phosphate buffer saline (PBS) with/without nucleic acid (pDNA or
siRNA) by vortexing for 30 seconds. The resulting dispersion was then sonicated using a
bath sonicator for 30 minutes. The total lipid concentration in the liposomes was 2 mM.
The total pDNA concentration was 40 ng/µl and that of siRNA was 400 nM, respectively,
in the liposomes containing corresponding nucleic acids.
9

2.2. Preparation of multi lamellar vesicles (MLVs)
MLVs were prepared by a thin film hydration method in order to study potential
fusogenicity enhancement. Briefly, a chloroform solution of cationic lipid DOTMA and
anionic lipid DPPS at an equal molar ratio with/without hydrophobic NPs at various
ratios of lipid molecules : NPs was prepared in a sterile glass vial. A thin uniform film
was then prepared by rapidly evaporating the chloroform under vacuum for 2 hours in
order to remove the excess solvent,. This film was then hydrated using 2 ml (for AgNPscontaining MLVs) or 4 ml (for AuNPs-containing MLVs) of citrate buffer (10 mM in
10% D2O, pH 4.0) by vortexing for 30 seconds. The total lipid concentration was 15
mM. The resulting dispersion was then sonicated using a bath sonicator for 30 minutes.
The morphology of the liposomes was observed using cryo-TEM (JEM-2100F, Jeol USA
Inc., MA, USA) and the phase transition was detected using 31P-NMR (Varian 500 MHz,
Agilent Technologies, CA, USA) analysis.

2.3. Dynamic light scattering (DLS)
A Zetasizer Nano ZS (Malvern Instruments Ltd., Worcestershire, UK) was used
to perform DLS experiments in order to measure the size of liposomes. A suspension of
each liposome preparation (0.5 ml) was deposed into disposable polystyrene cuvettes
(Sarstedt AG & Co., Newton, NC, USA) having a 1 cm path length. The temperature was
set to 25 °C for the analysis and samples were allowed to equilibrate for 60 seconds
before the measurement. The particle size was then determined at a manual setting of 15

10

counts with 10 seconds per count and a measurement angle of 173° Backscatter (NIBS
Default).

2.4. Cryogenic transmission electron microscopy (Cryo-TEM)
Cryo-TEM was performed in order to determine the morphology of the
liposomes. The samples were prepared at 37 °C using a Vitrobot (FEI Company), a PCcontrolled robot for sample vitrification. Quantifoil grids were used with 2-µm carbon
holes on 200 square mesh copper grids (Electron Microscopy Sciences, Hatfield, PA).
After immersing the grid into the sample, it was then removed, blotted to reduce film
thickness, and vitrified in liquid ethane. Imaging was performed in a cooled microscopy
stage (Model 915, Gatan Inc., Pleasanton, CA) at 200 kV using a JEOL JEM-2100F TEM
(Peabody, MA).

2.5. Phosphorus-31 nuclear magnetic resonance spectroscopy
The 31P-NMR spectra were acquired on an Agilent NMRS 500 NMR
spectrometer operating at 202.3 MHz using a 5-mm OneNMR probe. NMR data were
collected for 60 K scans with a 35.7-kHz sweep width using 131 K data points.
Acquisition time was 1.3 s with a relaxation delay of 0.5 s. The data were processed with
Mnova program V8.1 Mesterlab research SL. A line broadening of 50 Hz was applied to
all spectra. All spectra were indirectly referenced to H3PO4 set to 0 ppm. Data were
acquired without spinning.
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2.6. Cell transfection
Huh-7 cells at 2x105 cells/well concentration were seeded in 12 well plates and
transfected in the presence of 1 ml/well OPTIMEM-1 using 50 µl/well liposomes for
eGFP expressing pDNA experiments. For mFXRa1 protein expressing pDNA
experiments, Huh-7 cells were seeded at 4x105 cells/well concentration in 6 well plates
and transfected in the presence of 2 ml/well OPTIMEM-1 using 100 µl/well liposomes.
For eGFP specific silencing siRNA experiments, 12 well plate conditions as described
above were used and Huh-7 cells were first transfected with eGFP expressing pDNA at 2
µg/well concentration using GenJet. The medium was then replaced after 12 hours in
order to remove left-over GenJet reagent and the cells were transfected using 50 µl/well
liposomes comprising eGFP specific silencing siRNA.

2.7. Fluorescence microscopy
Cells transfected using eGFP expressing pDNA or eGFP silencing siRNA were
observed 48 hours after transfection under a fluorescence microscope (Eclipse TE2000-E,
Nikon Instruments Inc., NY, USA) at a 10x magnification set up in order to detect the
eGFP fluorescence in the cells. Images were taken in order to observe the relative eGFP
fluorescence in the cells.

2.8. FACS analysis
FACS analysis was performed in order to count eGFP-expressing cells using a
flow cytometer (BD FACSVerseTM, BD Biosciences, CA, USA). The well plates were
removed from the incubator 48 hours after transfection and the medium was discarded.
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The cells were then washed twice with 1 ml of PBS equilibrated at 37 °C. The cells were
then trypsinized using 1 ml of trypsin equilibrated at 37 °C. DMEM (1 ml) containing 10
% FBS, 1 % NEA, and 1 % PS equilibrated at 37 °C was added into the wells. The plate
was then shaken and the contents (total 2 ml) were transferred to 15 ml tubes. The tubes
were then centrifuged for 5 minutes at 1000 rpm and 5 °C, supernatant was discarded,
and 2 ml of PBS stored at 5 °C was added to these tubes. This step was repeated one
more time and then 2 ml of room temperature PBS was added to the tubes. The cells were
then suspended by pipetting up and down and then analyzed using the flow cytometer
with laser set up for counting eGFP expressing cells.

2.9. Western blot
The Western blotting technique was used in order to determine the protein levels
of mFXRa1 protein from the Huh7 whole cell lysates. Cells were ground 48 hours after
transfection in 1x sucrose-Tris buffer using a mechanical homogenizer. The whole cell
lysate was then centrifuged at 15000g for 15 minutes to obtain the clear lysate. The
protein concentration was determined using the Micro-BCA method from ThermoFischer’s Pierce Protein protocol. Thirty µg of protein was loaded onto an SDS PAGE gel
followed by a semi-wet transfer of the separated proteins from the gel to a PVDF
membrane. The membrane containing proteins were blocked in 5% milk/TBST buffer for
3 hours followed by treatment with the primary antibody of mFXRa1 (1:1000) in 5%
milk/TBST overnight at 4 °C. The membrane was then washed and incubated with the
secondary antibody (1:4000) in 5% milk for 1 hour at room temperature on a lab shaker.
The membranes were washed three times using 1x Tris-sucrose buffer containing (10%)
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Triton X-100 (TBST) and were then imaged using the chemi-luminescent substrate from
Thermo-Fischer Scientific. Protein expression was quantified using a Typhoon 9000-FLA
imager and normalized against GAPDH, as an internal housekeeping gene.

3. Results and Discussion
3.1. Schematic, size, and morphology of liposomes
Figure 1 depicts the chemical structures of the materials used and the schematic of
liposomes manufactured in this work. As shown in Figure 1, the hydrophobic NPs made
of gold (Au) and silver (Ag) are coated with hydrophobic chains of dodecanethiol
(Figures 1a and 1b, respectively). The chemical structures of the cationic lipid DOTMA,
the non-ionic lipid DSPC, and the anionic lipid DPPS are shown in Figures 1c, 1d, and
1e, respectively. Figure 1e shows the schematic of model liposomes examined in this
study, comprising active agents or therapeutic agents inside the aqueous core and
hydrophobic NPs in the bilayer. Since a typical liposomal bilayer width is 5 nm,
hydrophobic NPs of up to 5 nm diameter can be incorporated into this bilayer, which may
lead to bulging in the liposomal bilayer. Moreover, the presence of hydrophobic NPs in
the bilayer may increase the negative interfacial curvature of the bilayer and enhance its
fusogenicity by satisfying packing frustration during HII phase formation, subsequently
increasing the transfection efficiency of the liposomes. However, it is important to
determine the impact of incorporating the NPs into the bilayer on the size and
morphological characteristics of the liposomes. The size of liposomes manufactured in
this work was measured using DLS and their morphological characteristics were
observed using cryo-TEM. A representative DLS plot and cryo-TEM image of AuNPs-
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containing liposomes are shown in Figure 2. The size and shape of the liposomes was not
affected due to the incorporation of hydrophobic AuNPs into the bilayer. The size of the
liposomes with or without hydrophobic AuNPs was 203-225 nm and the polydispersity
index was 0.277-0.299. Similar results were obtained for liposomes comprising AgNPs or
MNPs with and without loading pDNA or siRNA.
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Figure 1.(a) AuNPs and (b) AgNPs coated with dodecanethiol. The chemical structures of
(c) DOTMA, (d) DSPC, and (e) DPPS. The schematic of a model liposome comprising
active agents or therapeutic agents (“cargo”) inside the aqueous core, with hydrophobic
NPs incorporated into the bilayer (f).
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Figure 2. (a) the size distribution of liposomes with and without AuNPs. Cryo-TEM
images of liposomes without (b) and with (c) AuNPs. The size and shape of the
liposomes was not affected due to the incorporation of hydrophobic AuNPs into the
bilayer.
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3.2. Enhancement in bilayer fusogenicity due to presence of NPs
The release of liposome content into the cytosol is problematic due to the
entrapment of liposomes and their contents within the endosomal compartments after
endocytosis. One of the major pathways for endosomal escape of the liposomal cargo
depends on the fusion between liposomal and endosomal bilayers. This fusion occurs via
HII phase formation (Figure 3a). As described herein, we hypothesized that after
endocytosis of hydrophobic NPs-containing liposomes, the presence of hydrophobic NPs
in the liposomal bilayer will promote fusion, thereby enhancing the release of liposomal
cargo into the cytosol. This mechanism of action has been illustrated in Figures 3b and
3c. Briefly, free flowing hydrophobic NPs present in the liposomal bilayer would be
expected to occupy the voids generated during HII phase formation between liposomal
and endosomal bilayers that would relax the packing frustration and ease the fusion
process.
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Figure 3. The liposomes taken inside the cell by endocytosis are entrapped in the
endosomal membranes, followed by endosomal escape. The liposomes then release their
cargo into the cytosol by fusing with the endosomes (a). This fusion between liposomal
and endosomal membranes occurs via inverted hexagonal (HII) phase formation that
generates packing frustration in both the bilayers (b). The presence of hydrophobic
nanoparticles relaxes this packing frustration and promotes fusion via HII phase formation
(c).

The enhancement in fusogenicity was assessed by measuring the HII phase
transition temperature and by 31P-NMR analysis. The morphology of MLVs produced for
this measurement has been depicted in Figure 4a. As shown in Figure 4b, these MLVs
depicted a characteristic 31P-NMR profile with a high field peak and a low field shoulder
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pattern, which transformed into a low field peak and a high field shoulder upon transition
to the HII phase. As illustrated in Figures 4b and 4c, the phase transition temperature was
reduced a from 50 °C to 40 °C upon incorporating 2 nm AuNPs at 10,000:1 lipid
molecules : NPs ratio into the bilayers. Although the phase transition temperature was not
further reduced, the intensity of the low field peak was higher for a 5,000:1 lipid
molecules : NPs ratio at 40 °C for this system (Figure 4d). Moreover, the phase transition
temperature was further reduced to 35 °C upon the incorporation of 4 nm AgNPs at a
10,000:1 lipid molecules : NPs ratio into the bilayers (Figures 4e). These data suggest
that the phase transition from bilayer to HII was induced not only by increasing the
concentration of the NPs but also by an increase in their size.

3.3. Hydrophobic NPs improved transfection efficiency
The expression of eGFP was significantly increased by using liposomes
containing AuNPs as compared to those without NPs. As depicted in Figure 5a, no
fluorescence was detected in cells transfected using blank liposomes, whereas the
positive control cells transfected using the commercial reagent Genjet exhibited a
substantial number of cells with green fluorescence. The number of cells showing green
fluorescence was higher for AuNPs-containing liposomes as compared to those using
liposomes without NPs. In order to quantify this effect, the cells showing green
fluorescence were measured using FACS analysis that confirmed the enhancement in
transfection efficiency due to the presence of AuNPs. As shown in Figure 5b, the number
of cells showing eGFP fluorescence were 1.28 times higher when transfected using
AuNPs-containing liposomes as compared to those transfected using liposomes without
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AuNPs. Student-t test was conducted in order to determine the statistical significance
with a p-value of 0.02.

Figure 4. (a) Cryo-TEM image of MLVs simulating endosomal entrapment condition.
The HII phase transition for MLVs (b) without NPs, (c) with 10,000:1 lipid molecules :
AuNPs, (d) 5,000:1 lipid molecules : AuNPs, and (e) 10,000:1 lipid molecules : AgNPs
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Figure 5. (a) fluorescence microscopic images and (b) bar chart summarizing the number
of cells with eGFP fluorescence counted using FACS for cells transfected with pDNA
using liposomes with and without AuNPs.

The enhancement in transfection efficiency of eGFP expressing pDNA due to the
presence of NPs in the liposomal bilayer was dependent on the size of the NPs and
correlated well with the results of 31P-NMR spectroscopy. As was revealed by 31P-NMR
spectroscopy, membrane fusogenicity was increased by increasing the size of NPs. It
might therefore be inferred that liposomes containing relatively larger NPs in their bilayer
would likely exhibit higher transfection efficiency. The dot plots obtained by FACS
analysis, shown in Figure 6a, illustrate the number of cells without eGFP fluorescence
(depicted as blue dots) as compared to those with eGFP fluorescence (depicted as pink
dots). The cells transfected using blank liposomes do not show any pink dots, whereas the
positive control cells transfected using commercial reagent GenJet depicted a significant
number of pink dots. Similarly, liposomes without any NPs showed very few pink dots as
22

compared to those for AgNPs-containing liposomes in their corresponding dot plots.
After counting these eGFP expressing cells, it was determined that the transfection
efficiency of eGFP expressing pDNA was enhanced 8-fold by incorporating 4 nm AgNPs
into the pDNA-containing liposomes (Figure 6b) as compared to a 1.28-fold increase by
incorporating 2 nm AuNPs (Figure 5b). Thus, liposomes containing the larger AgNPs
that displayed higher fusogenicity also exhibited higher transfection efficiency as
compared to liposomes containing smaller AuNPs.

Figure. 6 (a) Dot plots generated using FACS and (b) bar chart representing the number
of cells displaying eGFP fluorescence, counted using FACS for cells transfected with
pDNA using liposomes with and without AgNPs.

The enhancement in transfection efficiency for pDNA was further confirmed by
Western blotting. As shown in Figure 7a, pDNA transfected Huh-7 cells using liposomal
formulations containing AuNPs in their bilayers depicted higher protein expression of
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mFXRa1 as compared to those transfected using liposomes without NPs. The mFXRa1
protein expression on the Western blot was normalized using the housekeeping gene
GAPDH. When the protein expression was quantified it was noted that the transfection
efficiency of AuNPs-containing liposomes was twice that of liposomes without NPs
(Figure 7b). Thus, it was confirmed not only by using two different genes (eGFP and
mFXRa1) but also by using two different bio-analytical techniques (FACS and Western
blot) that the presence of NPs in the liposomal bilayers enhanced the transfection
efficiency of the corresponding pDNA.

Figure 7. (a) Western blot image and (b) bar plot of the quantification of mFXRa1 protein
for cells transfected with mFXRa1 expressing pDNA using liposomes with or without
AuNPs.

Another nucleic acid-based, bioactive compound, siRNA, was also investigated in
order to confirm the enhancement in transfection efficiency due to NPs-induced
fusogenicity of the liposomal bilayers. The eGFP specific silencing siRNA can inhibit the
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expression of eGFP protein. As shown in Figure 8, the number of cells showing eGFP
fluorescence as measured by FACS analysis was lower for NPs-containing liposomes as
compared to liposomes without NPs. These results also correlated well with the increase
in fusogenicity and eGFP expression noted in pDNA experiments. For example, AuNPs
with a 2 nm diameter exhibited lower fusogenicity (Figures 4c and 4e) and lower
transfection efficiency for pDNA (Figures 6a and 6b) as well as siRNA (Figure 8) as
compared to that for larger sized AgNPs with a 4 nm diameter. Although 5 nm MNPs
were larger than AgNPs of 4 nm diameter, AgNPs containing liposomes exhibited higher
transfection efficiency than liposomes containing MNPs of 5 nm diameter. This
discrepancy could be explained due to difference in the hydrophobic coating material of
the NPs. The AuNPs and AgNPs used in this work were coated with dodecanethiol
chains, whereas the MNPs were coated with oleic acid chains. The dodecanethiol chain is
shorter, with only 12 carbon atoms, as compared to oleic acid chains, with 18 carbon
atoms. Further, the dodecanethiol chain is completely saturated whereas the oleic acid
chain has one double bond that generates a kink in the chain. Thus, it might be inferred
that the longer chain with a kink may restrict the motion of MNPs in liposomal
membranes, and reduce their capacity to relax packing frustration, which might lead to
lower fusogenicity as compared to AgNPs. However, the nature of this observation could
not be assessed using
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P-NMR spectroscopy due to the magnetic nature of the MNPs,

which is incompatible with this analytical technique.
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Figure 8. Bar chart for number of cells with eGFP fluorescence counted using FACS for
cells transfected with pDNA using GenJet followed by siRNA using liposomes with and
without NPs.

5. Conclusions
Upon entering a cell, liposomes containing nucleic acid-based bioactive
molecules tend to be taken up by endocytosis, and their therapeutic action depends upon
escape from these endosomes into the cytosol. As demonstrated in this work, NPs
incorporation into liposomal membranes induced fusogenicity in the liposomal bilayers
and led to higher transfection efficiency and biological activity for two major nucleic acid
based drugs - pDNA and siRNA. These phenomena might be attributed to the use of
hydrophobic NPs in liposomal membranes as a novel method of endosomal escape. This
approach could further benefit currently popular strategies such as magnetically guided
delivery of nucleic acid-containing liposomes to their target tissues and enhance the
26

therapeutic effect due to NPs induced higher efficiency. Further, techniques such as
radio-frequency heating or laser excitation might further enhance the fusogenicity of
these metal NPs-containing liposomes due to the generation of heat and also due to the
rupture of endosomal membranes resulting from laser-induced vibration of membraneencapsulated metal NPs.
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Abstract
Reported herein is the use of chiral cationic polyamines for two intriguing
applications: fabrication of chiral covalently-linked microcapsules, and enantiospecific
delivery of siRNA to Huh 7 cells. The microcapsules are easily fabricated from
homochiral polymers, and the resulting architectures can be used for supramolecular
chiral catalysis and many other potential applications. Enantiospecific delivery of siRNA
to Huh 7 cells is seen by one ‘enantiomer’ of the polymers delivering siRNA with
significantly improved transfection efficiency and reduced toxicity compared to the
‘enantiomeric’ polymer and commercially available transfection reagents. Taken
together, the use of these easily accessible polyamine structures for diverse applications
is highlighted in this Letter herein and can lead to numerous future research efforts.
Graphical abstract

Keywords
Polyamine; Chirality; siRNA; Transfection.
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Polyethyleneimines (PEIs) are a well-studied class of polymers.1,2 These polymers
are synthesized commercially via the ring opening of aziridine (Scheme 1, Reaction 2),3–
5 although this process leads to highly branched polymers6 with significant
polydispersity indexes. The controlled synthesis of linear PEIs occurs via the cationic
ring opening of oxazolines,7–9 followed by hydrolysis of the resulting formamides
(Scheme 1, Reaction 1). Using chiral oxazolines as substrates for the polymerization
reaction provides straightforward access to homochiral PEIs,10–12 with chiral centers at
every polymer repeat unit.
Scheme 1

General synthetic methods for linear and branched polyethyleneimine (PEI)
The significant interest in PEIs is driven largely by various applications of PEIs in
fields

including

chiral

catalysis,13–16 drug

delivery,17,18 and

oligonucleotide

complexation and delivery.19,20 PEIs have also been covalently linked to form PEIderived microcapsules,21 which have been used for site-isolated catalysis.22,23 In one
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example, the Lewis basic PEI catalyzed a reaction in the same reaction vessel as a Lewis
acidic nickel catalyst, which was used to catalyze the second reaction.24,25
Use of the same PEI scaffold for multiple applications has rarely been reported,
although such multi-purpose polymers would have significant operational advantages.
Reported herein is the use of a single PEI scaffold for two purposes: the fabrication of
covalently-linked chiral microcapsules, and the efficient delivery of siRNA to Huh7
cells.26
The chiral PEIs were synthesized via the cationic polymerization of 4-benzyl-2oxazoline (1a) (both R and S configurations), followed by the hydrolysis of the initially
formed polyformamide (Scheme 2). The resulting polymers were characterized by 1H
NMR spectroscopy, and the results were in agreement with literature-reported
spectra.11 Using this methodology, polymers with 13 and 30 repeat units were formed,
with both R and S configured side chains.

Scheme 2

34

Scheme 2 Synthesis of chiral polymers 2a
Once synthesized, the homochiral PEIs were cross-linked to form homochiral
microcapsules

following

the

procedure

developed

by

McQuade

and

co-

workers.22 Briefly, polymers 2a were dissolved in methanol, and added to a solution of
2% Span 85, followed by the addition of 2,4-tolylene diisocyanate (TDI, compound 7)
(Equation 1), which cross linked the microcapsules to form a polyurea coating.25 The
resulting polyurethane-type structures have been shown to be stable in a variety of
aqueous media.27,28After thorough solvent evaporation, chiral microcapsules were
obtained.

Equation 1

Equation 1 Synthesis of chiral covalently-linked microcapsules

The resulting microcapsules were imaged using transmission electron microscopy
(TEM), and some images are shown in Figure 1. The diameters of the particles ranged
from 57 nm–250 nm, with an average diameter of 141 nm (± 35 nm; 62 particles
measured). These new supramolecular architectures contain narrow size distributions and
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uniform structures, in good agreement with literature-reported results for achiral
microcapsule analogues.21

Figure 1

Figure 1 TEM images of chiral microcapsules 8(Blue line represents a 500 nm scale)

The newly formed microcapsules contain a variety of features that make them
particularly amenable to supramolecular chiral catalysis, including: (a) multiple chiral
centers, covalently confined in a small space; (b) multiple amino groups that can be
protonated or deprotonated over a wide pH range;29 and (c) a hydrophobic core resulting
from the hydrophobic benzyl side chains.30
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To investigate the effect of capsule formation on the resulting supramolecular chiral
environment, the newly synthesized chiral microcapsules were used as catalysts for the
transamination reaction of ketoacids to amino acids (Equation 2). Obtaining good
enantioselectivities in such transamination reactions has been an ongoing research
problem.10 Preliminary results indicate that the microcapsule-catalyzed reactions
proceeded with significantly higher enantioselectivities compared to the polymercatalyzed reactions (up to 20% enantiomeric excess (ee) obtained for the synthesis of Lvaline, under conditions where the polymer itself yielded 4% ee). Efforts to optimize the
reaction conditions are in progress.

Equation 2

Equation 2 Enantioselective transamination of ketoacids 9 to amino acids 11

Interestingly, the chiral PEIs also functioned as efficient siRNA delivery agents.
Although there are many reported examples of PEIs used for siRNA and DNA
delivery,31–33 many of these delivery vehicles suffer from high cytotoxicity.34 The
37

development of gene delivery agents that are both effective and less toxic remains a
highly relevant research objective.

The following 4 polymers were investigated as potential siRNA delivery agents: R2a-13; S-2a-13; R-6-13; and S-6-13, where the R/S designation refers to the chirality of
the side chain and the number 13 refers to the number of repeat units in the polymers.
The efficacy of these polymers in transfecting an Alexa488-labeled control siRNA
sequence35 to Huh7 cells36 was measured by determining the intracellular fluorescence
24 hours post-transfection. The results obtained using the chiral polyamines were
compared to results obtained using commercially available transfection reagents: Genjet
siRNA Transfection Reagent (SignaGen Laboratories); HiPerFect Transfection Reagent
(Qiagen Laboratories);37 and Lipofectamine 2000 (Invitrogen Technologies).

Figure 2 shows a graph of the intracellular fluorescence of Huh7 cells following
their incubation with Alexa-labeled siRNA with various delivery reagents. The
intracellular fluorescence obtained with compounds S-6-13 and S-2a-13 is substantially
higher than the fluorescence observed with positive controls Lipofectamine and Genjet,
indicating the polymers’ ability to transfect siRNA efficiently (Table 1). More
interestingly, compounds R-2a-13 and R-6-13, which are identical except for the threedimensional configuration of the benzyl group, transfect siRNA with approximately the
same efficiency as Lipofectamine and Genjet, and substantially lower than the
“enantiomeric” polymers.
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Figure 2

Chart of the intracellular fluorescence of Huh7 cells after transfection with siRNA
(all PEIs were used at a 1000 nM final concentration)
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Table 1

Transfection
agent

Intracellular fluorescence (normalized to 1.00 for cells
alone)

S-6-13

1.26

S-2a-13

1.30

Lipofectamine

1.05

Genjet

1.04

R-2a-13

1.06

R-6-13

1.05

Table 1 Transfection efficiencies of chiral PEIs and commercial transfection agents

The chirality of the side chains of the PEIs thus has a direct and measurable effect on
the ability of PEIs to transfect siRNA efficiently: S chiral centers (compounds S-6-13
and S-2a-13) transfect siRNA more efficiently than the R analogues. Such a result may
seem intuitive: that the interaction of two chiral macromolecules (chiral PEI and chiral
siRNA) depends on the three-dimensional configuration of both molecules. This intuition
is borne out by the results of this study, which is the first direct proof that the chirality of
a polyamine directly impacts its transfection efficiency. Similar effects of the chirality on
transfection efficiency were recently observed for the lipid delivery agent 1,2-dioleoyl-3-
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trimethylammonium-propane (DOTAP).39 In that report, the R enantiomer performed
better than either the S enantiomer or the racemic DOTAP mixture.

The toxicity of the newly synthesized PEIs was tested using an MTT assay.40 After
24 hours of incubation, the absorbance of the cells was quantified and the cell viability
was calculated. Using 1000 nM of S-2a-13 reduced the cell viability to 88%, and 1000
nM of S-6-13 reduced it to 82%. By comparison, Lipofectamine reduced cell viability to
89%, and compounds R-2a-13 and R-6-13 reduced viability to 78% and 71%. Thus, the
toxicity of the chiral PEIs, like the transfection efficiency, depends on the threedimensional configuration of the benzylic side chains.

The differences in transfection efficiency and toxicity mean that the S- and Rconfigured PEIs likely have fundamentally different three-dimensional architectures. The
relationship between the chirality of individual stereocenters and the overall polymer
configuration has been studied for related polymers using circular dichroism
spectroscopy.41–43 These differences in chirality affect the polymers’ solubility44 and
their interactions with DNA,45 and as shown here, their transfection efficiencies.

In summary, chiral polymers 6 and 2a were synthesized via straightforward, wellprecedented procedures. These polymers were used for two novel applications: the
fabrication of chiral, covalently-linked microcapsules, and the transfection of siRNA to
Huh7 cells. The chiral microcapsules can be used for a number of potential applications
in supramolecular chiral catalysis and in supramolecular enantiomer separations. The
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chirality-dependent siRNA transfection also provides an intriguing platform for further
investigation. In particular, polymer S-2a-13 demonstrated good transfection efficiency
and limited toxicity, and will be used for further biochemical investigations. The results
of these and other experiments will be reported in due course.
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CHAPTER 3

FUTURE WORK

In the current dissertation work we demonstrated that the fusogenicity of
liposomal delivery vehicles could be enhanced by incorporating hydrophobic NPs in their
bilayers. The enhancement in fusogenicity of the liposomal bilayers was depicted by
promotion of HII phase formation using both gold and silver NPs coated with
dodecanethiol chains. The transfection efficiency of eGFP expressing pDNA, mFXRα1
expressing pDNA, and eGFP specific siRNA in Huh-7 cells was significantly enhanced
due to incorporation of gold, silver, and magnetic NPs in the liposomal bilayers. Thus,
this enhancement could be attributed to the NP-induced fusogenicity in the bilayer. The
fusogenicity was slightly increased by increasing the concentration of NPs in the bilayer
and was significantly increased by incorporating larger sized NPs. The NP size induced
increase in fusogenicity could be correlated with enhanced transfection efficiency of
eGFP expressing pDNA as well as eGFP specific siRNAs for the corresponding
liposomal formulations.

We hypothesize that the fusogenicity can be further enhanced by using radiation
and the future work will be focused on this aspect. MNPs exhibit Brownian and Neel
relaxations upon exposure to the alternating radiofrequency radiations that lead to
rotation of the entire particle and change in the direction of its magnetization,
respectively {Nedelcu, 2008 #10}. These relaxations cause movement of the MNPs in the
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surrounding medium as well as increase in their temperature {Fortin, 2008 #11}. Thus,
the MNPs can fill up the voids generated during HII phase formation thereby satisfying
the packing frustration. Moreover, the enhanced temperature and vibration of the MNPs
can induce rapid pore formation in the endosomal membrane during HII phase formation.
Similarly, upon exposure to the near infra-red and UV radiation, AuNPs demonstrate
increase in temperature {An, 2013 #12}. In the proposed future work the hydrophobic
NPs such as MNPs and AuNPs will be incorporated into the bilayer of liposomes
containing nucleic acid based drugs. These liposomes will be used to transfect the cells.
The cells will then be exposed to the radiofrequency and near infra red/UV radiation for
MNPs and AuNPs containing liposomes, respectively. The enhancement in transfection
efficiency due to the radiation will be determined by running the same experiment
without exposure to the radiation. The cells will be exposed to the radiation post
transfection at different starting time points and the optimum time and duration of
exposure will be determined. Further, in-vivo experiments will be conducted in mice by
dosing them with these specialized liposomes containing nucleic acid based drugs via tail
vein injection. The animals will then be exposed to the radiation and the enhancement in
protein production with or without radiation exposure will be compared. Fluorescent
labeled lipids and nucleic acid based drugs will be used in order to determine the location
of the liposomes and exposure to the radiation will be initiated when the fluorescence is
detected in the endosomes as tiny dots in the cells. Thus, homogeneous spreading of the
fluorescence in the cells post radiation exposure may indicate endosomal escape.
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Mammalian

hepatocytes

express

asialoglycoprotein

receptor

(ASGP-R)

exclusively and in high numbers {Ashwell, 1982 #13}. The human ASGP-R is a
transmembrane protein with two homologous subunits (H1 and H2), which recognizes
and binds desialylated glycoproteins with terminal galactose or N-acetylgalactosamine
residues {Ashwell, 1982 #13}. The uptake of receptor-ligand complex by the hepatocytes
occurs via receptor-mediated endocytosis after the binding process. The ASGP-R is then
recycled back to the surface, whereas the ligand is degraded into the lysosomes by the
enzymes {Geffen, 1992 #14}. The ASGP-R has been used for liver specific delivery for a
long time due to its abundant and exclusive expression on the hepatocytes and highly
efficient uptake via endocytosis {Wu, 2002 #15}. The major ligands for ASGP-R are
galactose, N-acetylgalactosamine and glucose and the key factors affecting ligandreceptor binding include isomeric forms of sugar, galactose density and branching, spatial
geometry and galactose linkages {D'Souza, 2015 #16}. Akinc et al. developed liver
targeting approach using an exogenous ligand containing a multivalent Nacetylgalactosamine (GalNAc)-cluster, which binds with high affinity to the ASGP-R
{Akinc, 2010 #18}. In this work the GalNAc moiety was conjugated to the distal end of a
2,000 MW polyethylene glycol (PEG) utilizing a distearyl (C18) lipid (GalNAc–PEG–
DSG) providing a stable hydrophobic anchor for the targeted PEG–lipid to the iLNP.
Such PEG-lipids with targeting ligand to the distal end of the PEG will be used in our
specialized liposomes containing hydrophobic NPs in order to target the liver.

In the third part of the future work, liver targeting approach using our specialized
liposomes will be combined with controlled radiation exposure. Typically process of
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ASGP ligand-receptor binding occurs within 8.7 minutes followed by cell internalization
in next 2.3 minutes {Schwartz, 1982 #19}. The dissociation of ASGP-R and its return to
the cell membrane then takes place in next 4.2 minutes {Schwartz, 1982 #19}. Hence, we
hypothesize that the hepatocyte targeting liposomes containing NPs will be taken up by
the cells in approximately 11 minutes post transfection and if the cells are exposed to the
radiation it may lead to endosomal escape and highly efficient transfection of nucleic acid
based drugs. Therefore, in-vitro work in intact hepatocytes will be conducted in order to
test the proof of concept using specialized liposomes containing targeting moiety and
NPs followed by in-vivo work using fluorescently labeled lipids/nucleic acid based drugs.
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SUMMARY AND CONCLUSIONS

Despite of the significant potential of nucleic acid based drugs as therapeutic
agents for several life threatening ailments, their successful application is majorly limited
due to insufficient delivery of these drugs to their site of action. One of the major barriers
in the path of their delivery is endosomal degradation, which occurs followed by cellular
uptake. Liposomal vehicles such as SNALPs (stable nucleic acid lipid particles)
developed by Tekmira is one of the leading strategies for therapeutic application due to
its feasibility of large scale and cGMP manufacture, storage stability for up to 2 years,
lower in-vivo toxicity, and higher potency and encapsulation efficiency. On the other
hand, poly-cationic polymers are majorly used in intact cells for transfection in order to
evaluate initial effectiveness of nucleic acid based drugs during discovery stages as well
as to understand the etiology of diseases. These poly-cationic polymers are highly
efficient in cellular uptake via interaction with negatively charged cell membrane and
endosomal escape via proton sponge effect mechanism, however, exhibit higher toxicity.
In this work we demonstrated that the efficiency of SNALP type vehicles was
significantly enhanced using hydrophobic NPs, which could be attributed to the ability of
these vehicles in efficiently delivering the cargo to the site of action via improved
endosomal escape. Whereas, our novel chiral polyamines exhibited higher transfeciton
efficiency as well as lower toxicity. Thus, our novel liposomal- and chiral polyamine
based vehicles could be beneficial in improving the efficiency of nucleic acid based drugs
for therapeutic application and discovery purposes, respectively.
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In manuscript 1 we demonstrated that the fusogenicity of liposomal delivery
vehicles could be enhanced by incorporating hydrophobic NPs in their bilayers. The
enhancement in fusogenicity of the liposomal bilayers could be depicted by promotion of
HII phase formation using both gold and silver NPs coated with dodecanethiol chains. The
transfection efficiency of eGFP expressing pDNA, mFXRα1 expressing pDNA, and
eGFP specific siRNA in Huh-7 cells was significantly enhanced due to incorporation of
gold, silver, and magnetic NPs in the liposomal bilayers. Thus, this enhancement could
be attributed to the NP-induced fusogenicity in the bilayer. The fusogenicity was slightly
increased by increasing the concentration of NPs in the bilayer and was significantly
increased due to using larger sized NPs. The NP size induced increase in fusogenicity
could be correlated with enhanced transfection efficiency of eGFP expressing pDNA as
well as eGFP specific siRNAs for the corresponding liposomal formulations. This
approach could further benefit currently popular strategies such as magnetically guided
delivery of nucleic acid-containing liposomes to their target tissues and enhance the
therapeutic effect due to NPs induced higher transfection efficiency. Further, techniques
such as radio-frequency heating or laser excitation might further enhance the fusogenicity
of these metal NPs-containing liposomes due to the generation of heat and also due to the
rupture of endosomal membranes resulting from laser-induced vibration of membraneencapsulated metal NPs.

In manuscript 2 we showed that Chiral Polyamines presented another efficient
technique for the delivery of siRNA with less toxicity post cell transfection. chiral
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polymers 6 and 2a were synthesized via straightforward, were used for two novel
applications: the fabrication of chiral, covalently-linked microcapsules, and the
transfection of siRNA to Huh7 cells. The chirality-dependent siRNA transfection also
provides an intriguing platform for further investigation. In particular, polymer S-2a-13
demonstrated good transfection efficiency and limited toxicity, and will be used for
further biochemical investigations. The results of these and other experiments will be
reported in due course.
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APPENDICES

The first part of the Appendix focusses on investigating role of Nuclear receptors
Farnesoid X Receptors (FXR) and Estrogen Receptors in transcriptional regulation of
Bile Salt Export pump (BSEP). The human Bile Salt Export pump (BSEP) is a key player
in maintaining the overall Bile acid homeostasis of the body and is regulated by
Farnesoid X Receptors (FXR) in an isoform-dependent manner. Disruption of BSEP
leads to development of severe pathological conditions such as Intrahepatic Cholestasis
of Pregnancy (ICP) and Hepatocellular Carcinoma (HCC) showing increased serum bile
acid levels in the body. The goals of the proposed research focuses on investigating the
underlying mechanisms involved in the etiology of Hepatocellular Carcinoma by
establishing the connection between FXR, the key Bile acid regulator and Estrogen
Receptors and its variants in the Intrahepatic Cholestasis of Pregnancy (ICP).
The final part of the appendix presents a published manuscript that focusses on
evaluation of biological molecules (chalcones, flavones and chromenes) in development,
as potent farnesoid x receptor (FXR) antagonists.
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Abstract
Among diseases unique to pregnancy, intrahepatic cholestasis of pregnancy is the most
prevalent disorder with elevated serum bile acid levels. We have previously shown that
estrogen 17β-estradiol (E2) transrepresses bile salt export pump (BSEP) through an
interaction between estrogen receptor (ER)-α and farnesoid X receptor (FXR) and
transrepression of BSEP by E2/ERα is an etiological contributing factor to intrahepatic
cholestasis of pregnancy. Currently the mechanistic insights into such transrepression are
not fully understood. In this study, the dynamics of coregulator recruitment to BSEP
promoter after FXR activation and E2 treatment were established with quantitative
chromatin immunoprecipitation assays. Coactivator peroxisome proliferator-activated
receptor-γ coactivator-1 was predominantly recruited to the BSEP promoter upon FXR
activation, and its recruitment was decreased by E2 treatment. Meanwhile, recruitment of
nuclear receptor corepressor was markedly increased upon E2 treatment. Functional
evaluation of ERα and ERβ chimeras revealed that domains AC of ERα are the
determinants for ERα-specific transrepression on BSEP. Further studies with various
truncated ERα proteins identified the domains in ERα responsible for ligand-dependent
and ligand-independent transrepression. Truncated ERα-AD exhibited potent ligandindependent transrepressive activity, whereas ERα-CF was fully capable of
transrepressing BSEP ligand dependently in vitro in Huh 7 cells and in vivo in mice. Both
ERα-AD and ERα-CF proteins were associated with FXR in the coimmunoprecipitation
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assays. In conclusion, E2 repressed BSEP expression through diminishing peroxisome
proliferator-activated receptor-γ coactivator-1 recruitment with a concurrent increase in
nuclear receptor corepressor recruitment to the BSEP promoter. Domains AD and CF in
ERα mediated ligand-independent and ligand-dependent transrepression on BSEP,
respectively, through interacting with FXR.
Among diseases unique to pregnancy, intrahepatic cholestasis of pregnancy (ICP) is the
most prevalent disorder (1,–3) in pregnant women. ICP predominantly occurs in the late
stages of pregnancy and spontaneously recovers after birth (3). Although ICP is a
relatively mild disorder for the mother, it poses significant risks of complications to the
fetus, including preterm delivery, respiratory stress, and prenatal mortality (1,–4). One of
the characteristic clinical manifestations of ICP is markedly elevated levels of serum bile
acids, indicating the disruption of bile acid homeostasis in ICP patients (5,–7).
Bile acid homeostasis is achieved through a tightly regulated enterohepatic circulation of
bile acids. Canalicular secretion of bile acids through bile salt export pump (BSEP) is the
rate-limiting step in such circulation (8, 9). Modulation of BSEP expression or function
by inherited or acquired factors has a profound impact on the biliary and intrahepatic bile
acid levels. Indeed, the impairment of BSEP expression or function has been directly
linked to such diseases as progressive familial intrahepatic cholestasis type 2 (10, 11),
benign recurrent intrahepatic cholestasis (12, 13), and ICP (14,–16).
Under physiological conditions, BSEP expression is coordinately regulated by distinct
but related transactivation pathways (17,–21), notably the bile acids/farnesoid X receptor
(FXR) signaling pathway (17, 18). Activation of FXR by bile acids strongly induces
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BSEP expression in vitro and in vivo (17, 18). Such feed-forward regulation of BSEP by
bile acid/FXR is considered a major mechanism for preventing excessive accumulation of
toxic bile acids in hepatocytes.
We previously reported that BSEP expression was significantly repressed in the late
stages of pregnancy in mice and inversely correlated with serum estrogen 17β-estradiol
(E2) levels (22). Further studies showed that E2 repressed BSEP expression in vitro and
in vivo through estrogen receptor (ER)-α, and such repression was resulted from a cross
talk between the E2/ERα and bile acids/FXR signaling pathway. It is thus concluded that
E2-mediated transrepression of BSEP represents an etiological contributing factor to ICP.
However, the underlying mechanisms of such transrepression are not fully understood.
In this study, we demonstrated that E2 repressed BSEP expression through decreasing
recruitment of coactivator peroxisome proliferator-activated receptor gamma coactivator1 (PGC-1) with a concurrent increase in recruitment of nuclear receptor corepressor
(NCoR) to the BSEP promoter. Further studies revealed that domains AD and CF in ERα
mediated

ligand-independent

and

ligand-dependent

transrepression

on

BSEP,

respectively, through interacting with FXR.

References
1. Hay JE. Liver disease in pregnancy. Hepatology. 2008;47:1067–1076. [PubMed]
2. Joshi D, James A, Quaglia A, Westbrook RH, Heneghan MA. Liver disease in
pregnancy. Lancet. 2010;375:594–605. [PubMed]
62

3. Geenes V, Williamson C. Intrahepatic cholestasis of pregnancy. World J Gastroenterol.
2009;15:2049–2066. [PMC free article] [PubMed]
4. Rook M, Vargas J, Caughey A, Bacchetti P, Rosenthal P, Bull L. Fetal outcomes in
pregnancies complicated by intrahepatic cholestasis of pregnancy in a Northern
California cohort. PLoS One. 2012;7:e28343. [PMC free article] [PubMed]
5. Lunzer M, Barnes P, Byth K, O'Halloran M. Serum bile acid concentrations during
pregnancy and their relationship to obstetric cholestasis. Gastroenterology. 1986;91:825–
829. [PubMed]
6. Heikkinen J, Maentausta O, Ylostalo P, Janne O. Changes in serum bile acid
concentrations during normal pregnancy, in patients with intrahepatic cholestasis of
pregnancy and in pregnant women with itching. Br J Obstet Gynaecol. 1981;88:240–245.
[PubMed]
7. Glantz A, Marschall HU, Mattsson LA. Intrahepatic cholestasis of pregnancy:
Relationships between bile acid levels and fetal complication rates. Hepatology.
2004;40:467–474. [PubMed]
8. Meier PJ, Stieger B. Bile salt transporters. Annu Rev Physiol. 2002;64:635–661.
[PubMed]
9. Kullak-Ublick GA, Stieger B, Meier PJ. Enterohepatic bile salt transporters in normal
physiology and liver disease. Gastroenterology. 2004;126:322–342. [PubMed]
10. Strautnieks SS, Bull LN, Knisely AS, et al. A gene encoding a liver-specific ABC
transporter is mutated in progressive familial intrahepatic cholestasis. Nat Genet.
1998;20:233–238. [PubMed]

63

11. Jansen PL, Strautnieks SS, Jacquemin E, et al. Hepatocanalicular bile salt export
pump deficiency in patients with progressive familial intrahepatic cholestasis.
Gastroenterology. 1999;117:1370–1379. [PubMed]
12. van Mil SW, van der Woerd WL, van der Brugge G, et al. Benign recurrent
intrahepatic cholestasis type 2 is caused by mutations in ABCB11. Gastroenterology.
2004;127:379–384. [PubMed]
13. Kubitz R, Keitel V, Scheuring S, Köhrer K, Häussinger D. Benign recurrent
intrahepatic cholestasis associated with mutations of the bile salt export pump. J Clin
Gastroenterol. 2006;40:171–175. [PubMed]
14. Eloranta ML, Häkli T, Hiltunen M, Helisalmi S, Punnonen K, Heinonen S.
Association of single nucleotide polymorphisms of the bile salt export pump gene with
intrahepatic cholestasis of pregnancy. Scand J Gastroenterol. 2003;38:648–652.
[PubMed]
15. Pauli-Magnus C, Lang T, Meier Y, et al. Sequence analysis of bile salt export pump
(ABCB11) and multidrug resistance p-glycoprotein 3 (ABCB4, MDR3) in patients with
intrahepatic cholestasis of pregnancy. Pharmacogenetics. 2004;14:91–102. [PubMed]
16. Dixon PH, van Mil SW, Chambers J, et al. Contribution of variant alleles of ABCB11
to susceptibility to intrahepatic cholestasis of pregnancy. Gut. 2009;58:537–544.
[PubMed]
17. Ananthanarayanan M, Balasubramanian N, Makishima M, Mangelsdorf DJ, Suchy
FJ. Human bile salt export pump promoter is transactivated by the farnesoid X
receptor/bile acid receptor. J Biol Chem. 2001;276:28857–28865. [PubMed]

64

18. Plass JR, Mol O, Heegsma J, et al. Farnesoid X receptor and bile salts are involved in
transcriptional regulation of the gene encoding the human bile salt export pump.
Hepatology. 2002;35:589–596. [PubMed]
19. Deng R, Yang D, Radke A, Yang J, Yan B. The hypolipidemic agent guggulsterone
regulates the expression of human bile salt export pump: dominance of transactivation
over farsenoid X receptor-mediated antagonism. J Pharmacol Exp Ther. 2007;320:1153–
1162. [PMC free article] [PubMed]
20. Song X, Kaimal R, Yan B, Deng R. Liver receptor homolog 1 transcriptionally
regulates human bile salt export pump expression. J Lipid Res. 2008;49:973–984. [PMC
free article] [PubMed]
21. Weerachayaphorn J, Cai SY, Soroka CJ, Boyer JL. Nuclear factor erythroid 2-related
factor 2 is a positive regulator of human bile salt export pump expression. Hepatology.
2009;50:1588–1596. [PMC free article] [PubMed]
22. Song X, Vasilenko A, Chen Y, et al. Transcriptional dynamics of bile salt export
pump during pregnancy: Mechanisms and implications in intrahepatic cholestasis of
pregnancy. Hepatology. 2014;60(6):1993–2007. [PMC free article] [PubMed]
23. Deng R, Yang D, Yang J, Yan B. Oxysterol 22(R)-hydroxycholesterol induces the
expression of the bile salt export pump through nuclear receptor farsenoid X receptor but
not liver X receptor. J Pharmacol Exp Ther. 2006;317:317–325. [PMC free article]
[PubMed]
24. Kaimal R, Song X, Yan B, King R, Deng R. Differential modulation of farnesoid X
receptor signaling pathway by the thiazolidinediones. J Pharmacol Exp Ther.
2009;330:125–134. [PMC free article] [PubMed]

65

25. Chen Y, Song X, Valanejad L, et al. Bile salt export pump is dysregulated with
altered farnesoid X receptor isoform expression in patients with hepatocellular
carcinoma. Hepatology. 2013;57:1530–1541. [PMC free article] [PubMed]
26. Song X, Chen Y, Valanejad L, et al. Mechanistic insights into isoform-dependent and
species-specific regulation of bile salt export pump by farnesoid X receptor. J Lipid Res.
2013;54:3030–3044. [PMC free article] [PubMed]
27. Makishima M, Okamoto AY, Repa JJ, et al. Identification of a nuclear receptor for
bile acids. Science. 1999;284:1362–1365. [PubMed]
28. Mi LZ, Devarakonda S, Harp JM, et al. Structural basis for bile acid binding and
activation of the nuclear receptor FXR. Mol Cell. 2003;11:1093–1100. [PubMed]
29. Kanaya E, Shiraki T, Jingami H. The nuclear bile acid receptor FXR is activated by
PGC-1α in a ligand-dependent manner. Biochem J. 2004;382:913–921. [PMC free
article] [PubMed]
30. Ananthanarayanan M, Li S, Balasubramaniyan N, Suchy FJ, Walsh MJ. Liganddependent activation of the farnesoid X-receptor directs arginine methylation of histone
H3 by CARM1. J Biol Chem. 2004;279:54348–54357. [PubMed]
31. Renga B, Migliorati M, Mencarelli A, et al. Farnesoid X receptor suppresses
constitutive androstane receptor activity at the multidrug resistance protein-4 promoter.
Biochim Biophys Acta. 2011;1809:157–165. [PubMed]
32. Sepe V, Bifulco G, Renga B, D'Amore C, Fiorucci S, Zampella A. Discovery of
sulfated sterols from marine invertebrates as a new class of marine natural antagonists of
farnesoid-X-receptor. J Med Chem. 2011;54:1314–1320. [PubMed]

66

33. Caron S, Huaman Samanez C, Dehondt H, et al. Farnesoid X receptor inhibits the
transcriptional activity of carbohydrate response element binding protein in human
hepatocytes. Mol Cell Biol. 2013;33:2202–2211. [PMC free article] [PubMed]
34. Huang HJ, Norris JD, McDonnell DP. Identification of a negative regulatory surface
within estrogen receptor alpha provides evidence in support of a role for corepressors in
regulating cellular responses to agonists and antagonists. Mol Endocrinol. 2002;16:1778–
1792. [PubMed]
35. Lu TT, Makishima M, Repa JJ, et al. Molecular basis for feedback regulation of bile
acid synthesis by nuclear receptors. Mol Cell. 2000;6:507–515. [PubMed]
36. Goodwin B, Jones SA, Price RR, et al. A regulatory cascade of the nuclear receptors
FXR, SHP-1, and LRH-1 represses bile acid biosynthesis. Mol Cell. 2000;6:517–526.
[PubMed]
37. Valentine JE, Kalkhoven E, White R, Hoare S, Parker MG. Mutations in the estrogen
receptor ligand binding domain discriminate between hormone-dependent transactivation
and transrepression. J Biol Chem. 2000;275:25322–25329. [PubMed]
38. Williams CC, Basu A, El-Gharbawy A, Carrier LM, Smith CL, Rowan BG.
Identification of four novel phosphorylation sites in estrogen receptor α: impact on
receptor-dependent gene expression and phosphorylation by protein kinase CK2. BMC
Biochem. 2009;10:36. [PMC free article] [PubMed]
39. Duplessis TT, Williams CC, Hill SM, Rowan BG. Phosphorylation of estrogen
receptor α at serine 118 directs recruitment of promoter complexes and gene-specific
transcription. Endocrinology. 2011;152:2517–2526. [PMC free article] [PubMed]

67

40. Savkur RS, Thomas JS, Bramlett KS, Gao Y, Michael LF, Burris TP. Liganddependent coactivation of the human bile acid receptor FXR by the peroxisome
proliferator-activated receptor γ coactivator-1α. J Pharmacol Exp Ther. 2005;312:170–
178. [PubMed]
41. Cvoro A, Tzagarakis-Foster C, Tatomer D, Paruthiyil S, Fox MS, Leitman DC.
Distinct roles of unliganded and liganded estrogen receptors in transcriptional repression.
Mol Cell. 2006;21:555–564. [PubMed]
42. Bauer UM, Daujat S, Nielsen SJ, Nightingale K, Kouzarides T. Methylation at
arginine 17 of histone H3 is linked to gene activation. EMBO Rep. 2002;3:39–44. [PMC
free article] [PubMed]
43. Tcherepanova I, Puigserver P, Norris JD, Spiegelman BM, McDonnell DP.
Modulation of estrogen receptor-α transcriptional activity by the coactivator PGC-1. J
Biol Chem. 2000;275:16302–16308. [PubMed]
44. Uht RM, Webb P, Nguyen P, et al. A conserved lysine in the estrogen receptor DNA
binding domain regulates ligand activation profiles at AP-1 sites, possibly by controlling
interactions with a modulating repressor. Nucl Recept. 2004;2:2. [PMC free article]
[PubMed]
45. Wärnmark A, Wikström A, Wright AP, Gustafsson JA, Härd T. The N-terminal
regions of estrogen receptor α and β are unstructured in vitro and show different TBP
binding properties. J Biol Chem. 2001;276:45939–45944. [PubMed]
46. Lanz RB, McKenna NJ, Onate SA, et al. A steroid receptor coactivator, SRA,
functions as an RNA and is present in an SRC-1 complex. Cell. 1999;97:17–27.
[PubMed]

68

47. Taylor SE, Martin-Hirsch PL, Martin FL. Oestrogen receptor splice variants in the
pathogenesis of disease. Cancer Lett. 2010;288:133–148. [PubMed]
48. Flouriot G, Brand H, Denger S, et al. Identification of a new isoform of the human
estrogen receptor-α (hER-α) that is encoded by distinct transcripts and that is able to
repress hER-α activation function 1. EMBO J. 2000;19:4688–4700. [PMC free article]
[PubMed]
49. Villa E, Colantoni A, Grottola A, et al. Variant estrogen receptors and their role in
liver disease. Mol Cell Endocrinol. 2002;193:65–69. [PubMed]
50. Trauner M, Claudel T, Fickert P, Moustafa T, Wagner M. Bile acids as regulators of
hepatic lipid and glucose metabolism. Dig Dis. 2010;28:220–224. [PubMed].
51. Teodoro JS, Rolo AP, Palmeira CM. Hepatic FXR: key regulator of whole-body
energy metabolism. Trends Endocrinol Metab. 2011;22:458–466. [PubMed]
52. Stanimirov B, Stankov K, Mikov M. Pleiotropic functions of bile acids mediated by
the farnesoid X receptor. Acta Gastroenterol Belg. 2012;75:389–398. [PubMed]
53. Huang W, Ma K, Zhang J, et al. Nuclear receptor-dependent bile acid signaling is
required for normal liver regeneration. Science. 2006;312:233–236. [PubMed]
54. Yang F, Huang X, Yi T, Yen Y, Moore DD, Huang W. Spontaneous development of
liver tumors in the absence of the bile acid receptor farnesoid X receptor. Cancer Res.
2007;67:863–867. [PubMed]

APPENDIX 2

69

Manuscript 2: Transcriptional Dynamics of Bile Salt Export Pump during Pregnancy:
Mechanisms and Implications in Intrahepatic Cholestasis of Pregnancy.

Journal of Hepatology
Published in final edited form as:
Hepatology. 2014 Dec; 60(6): 1993–2007.
Published online 2014 May 19. doi: 10.1002/hep.27171
PMCID: PMC4194188
NIHMSID: NIHMS587092
Transcriptional Dynamics of Bile Salt Export Pump during Pregnancy:
Mechanisms and Implications in Intrahepatic Cholestasis of Pregnancy

Xiulong Song,1 Alexander Vasilenko,1 Yuan Chen, Leila Valanejad, Ruchi Verma,
Bingfang Yan, and Ruitang Deng
Department of Biomedical and Pharmaceutical Sciences, Center for Pharmacogenomics
and Molecular Therapy, College of Pharmacy, University of Rhode Island, 7 Greenhouse
Road, Kingston, RI 02881
Xiulong Song: songxiulong@hotmail.com; Alexander Vasilenko:
alex_vasilenko@yahoo.com; Yuan Chen: chenyuan@ymail.com; Leila Valanejad:
leilavalanejad@gmail.com; Ruchi Verma: ruchi9991@gmail.com; Bingfang Yan:
byan@uri.edu; Ruitang Deng: dengr@mail.uri.edu

Contact Information:

70

Ruitang Deng, Department of Biomedical and Pharmaceutical Sciences, Center for
Pharmacogenomics and Molecular Therapy, College of Pharmacy, University of Rhode
Island, Kingston, RI 02881. Tel: 401-874-4950. Fax: 401-874-5787.
DengR@mail.uri.edu.
1 Both contributed equally.
Abstract
Bile salt export pump (BSEP) is responsible for biliary secretion of bile acids, a rate
limiting step in the enterohepatic circulation of bile acids and transactivated by nuclear
receptor farnesoid x receptor (FXR). Intrahepatic cholestasis of pregnancy (ICP) is the
most prevalent disorder among diseases unique to pregnancy and primarily occurs in the
third trimester of pregnancy with a hallmark of elevated serum bile acids. Currently, the
transcriptional regulation of BSEP during pregnancy and its underlying mechanisms and
involvement in ICP are not fully understood. In this study, the dynamics of BSEP
transcription in vivo in the same group of pregnant mice before, during and after gestation
were established with in vivo imaging system (IVIS). BSEP transcription was markedly
repressed in the later stages of pregnancy and immediately recovered after parturition,
resembling the clinical course of ICP in human. The transcriptional dynamics of BSEP
was inversely correlated with serum 17β-estradiol (E2) levels before, during and after
gestation. Further studies showed that E2 repressed BSEP expression in human primary
hepatocytes, Huh 7 cells and in vivo in mice. Such transrepression of BSEP by E2 in vitro
and in vivo required estrogen receptor α (ERα). Mechanistic studies with chromatin
immunoprecipitation (ChIP), protein co-immunoprecipitation (Co-IP) and bimolecular
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fluorescence complementation (BiFC) assays demonstrated that ERα directly interacted
with FXR in living cells and in vivo in mice. In conclusion, BSEP expression was
repressed by E2 in the late stages of pregnancy through a non-classical E2/ERα
transrepressive pathway, directly interacting with FXR. E2-mediated repression of BSEP
expression represents an etiological contributing factor to ICP and therapies targeting the
ERα/FXR interaction may be developed for prevention and treatment of ICP.
Keywords: BSEP, Bile acids, 17β-estradiol, FXR, ERα
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Highlights
•

New series of chalcone and chromene are first reported as potent FXR
antagonists.

•

A chromene compound (11c) significantly reduce the plasma and hepatic
triglyceride level and plasma ALT level in KKay diabetic mice.

•

Pharmacological role of FXR antagonist and its potential in the disease treatment
is revealed.

Abstract
Farnesoid X receptor (FXR), a nuclear receptor mainly distributed in liver and intestine,
has been regarded as a potential target for the treatment of various metabolic diseases,
cancer and infectious diseases related to liver. Starting from two previously identified
chalcone-based FXR antagonists, we tried to increase the activity through the design and
synthesis of a library containing chalcones, flavones and chromenes, based on
substitution manipulation and conformation (ring closure) restriction strategy. Many
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chalcones and four chromenes were identified as microM potent FXR antagonists, among
which chromene 11c significantly decreased the plasma and hepatic triglyceride level in
KKay mice.
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